IBM releases novel AI-powered technology to accelerate medical research for COVID-19

IBM has today released a new set of cloud- and AI-powered technologies to help researchers, doctors and scientists accelerate COVID-19 drug discovery. These novel resources, from across IBM and available beginning today (Friday 3 April)...

UK offers accelerated patent protection for eco-friendly innovations

Using the Green Channel to accelerate a UK patent application. AdamsonJones was able to obtain patent protection for client, LLEO Ltd, in just 15 months from the moment the Green Channel was used. This acceleration was crucial as...

Tackling the trillion dollar Alzheimer’s disease

It’s almost impossible to conceive the complexity that lies ahead in the challenge to address Alzheimer’s disease. But, picture standing in front of an old mansion house, completely overgrown with ivy, trees, and shrubs....

Build-up of brain proteins affects genes in Alzheimer’s disease

New research has shed fresh light on how the build-up of two proteins in the brain might affect the activity of genes involved in Alzheimer’s disease. Researchers at the University of Exeter worked in collaboration...

Artificial intelligence yields new antibiotic

A deep-learning model identifies a powerful new drug that can kill many species of antibiotic-resistant bacteria. Using a machine-learning algorithm, MIT researchers have identified a powerful new antibiotic compound. In laboratory tests, the drug killed...

TABBY CAT OR TIGER?

Medics need to be fleet of foot when it comes to determining whether they are dealing with something tame or wild, but the traditional route to identifying bacteria takes time. Now a team of...

How the brain’s immune system could be harnessed to improve memory

When it comes to memory, immune cells are known as the “bad cops” of the brain. But new research shows they could also be turned into “good cops” to power memory and learning. Inflammation can...

Are your innovations protected?

Innovation is something that defines the biosciences sector. The UK biotechnology and medical industries are among some of the most progressive in the world with billions invested annually on creating industry-leading drugs, techniques, therapies, and...

Will 2020 be the Year You Make the Most of Innovation Tax Reliefs

It’s the start of a new decade and with that comes the chance to have a fresh look at everything that is happening in your business.  It is likely to be the most active decade...

Shanks v Unilever – An opening of the claim floodgates?

Varuni Paranavitane, IP Solicitor,  AA Thornton At the end of last year Professor Shanks was awarded £2 million for an invention relating to a glucose sensor made while employed working for Unilever.  What does this mean...

UK accounts for over 12% of global cell and gene therapy clinical trials

The UK and the NHS are providing the right environment and infrastructure to allow innovative cell and gene therapies to reach patients. International companies recognise the appeal of the UK cell and gene therapy...

Hyperactive FOXA1 reprograms endocrine-resistant breast cancer to become metastatic

A team led by researchers at Baylor College of Medicine and Harvard Medical School has unveiled a novel mechanism that helps explain how endocrine-resistant breast cancer acquires metastatic behavior, opening the possibility of new...

Unprecedented exploration generates most comprehensive map of cancer genomes to date

An international team has completed the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment. Published in Nature, more...

The hidden way to fill vacancies, train and retain

The BSc (Hons) Biomedical Science (pathology lab based) degree apprenticeship has been developed through consultation with pathology laboratory employers and is co-delivered, meeting the requirements for a Healthcare Science Practitioner (Biomedical Scientist) apprenticeship. The programme...

Next Chapter of Intarcia’s Mini Pump for Diabetes Begins

More than 2 years after the FDA derailed the trajectory of its novel treatment system for type 2 diabetes (T2D), Intarcia Therapeutics announced that regulators have accepted a resubmitted new drug application for the...

Biosimilars set to make significant UK impact

Biosimilar medicines - equivalent biological products which have no meaningful differences from the original or reference product in terms of quality, safety or efficacy - are playing an important role in providing choice for...